Fremanezumab for prophylaxis of migraine in adults
Sign Up to like & getrecommendations! Published in 2020 at "Prescriber"
DOI: 10.1002/psb.1818
Abstract: Fremanezumab (Ajovy) is a new anti‐CGRP monoclonal antibody therapy indicated for the prophylaxis of migraine in adults. This article outlines its properties, efficacy, adverse effects and place in therapy. read more here.
Keywords: migraine adults; prophylaxis migraine; fremanezumab prophylaxis;